Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Reports from Herlev University highlight recent research in cancer vaccines
July 22nd, 2008
According to a study from Herlev, Denmark, "The current ''gold standard'' for generation of dendritic cell (DC) used in DC-based cancer vaccine studies is maturation of monocyte-derived DCs with tumor necrosis factor-alpha (TNF-alpha)/IL-1 beta/IL-6 and prostaglandin E-2 (PGE(2)). Recently, a protocol for producing so-called alpha-Type-1 polarized dendritic cells (alpha DC1) in serum-free medium was published based on maturation of monocyte-derived DCs with TNF-alpha/IL-1-beta/polyinosinic:polycytidylic acid (poly-I:C)/interferon (IFN)-alpha and IFN-gamma." "This DC maturation cocktail was described to fulfill the criteria for optimal DC generation and to be superior to...
Source: Cancer Weekly (2008-07-22)
|
